Ultragenyx Wins FDA Approval for GENGLYCOS Gene Therapy
Novato, California, August 19, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) granted...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Novato, California, August 19, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) granted...
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...
NOVATO, Calif., February 3, 2026 — Ultragenyx Pharmaceutical Inc. has reported positive long-term clinical data for UX111, an investigational...
NEEDHAM, Mass., October 9, 2025 — Stealth BioTherapeutics Inc. has announced the launch of Mito Assist™, a comprehensive patient...
LUND, Sweden, Sept. 24, 2025 — Hansa Biopharma has announced that imlifidase successfully met its primary endpoint in the...
NEEDHAM, Mass., September 19, 2025 – Stealth BioTherapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA)...
September 9, 2025 – In a significant advancement for neuro-oncology, Modeyso (dordaviprone) has been included in the National Oncology...
